<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01561833</url>
  </required_header>
  <id_info>
    <org_study_id>0901004690</org_study_id>
    <nct_id>NCT01561833</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients</brief_title>
  <official_title>A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a pilot study of sorafenib 400mg PO twice daily in refractory T-cell&#xD;
      lymphomas including peripheral T-cell lymphoma (PTCL), angioimmunoblastic lymphadenopathy&#xD;
      (AILD), cutaneous T cell lymphoma (CTCL), anaplastic large cell lymphoma (ALCL) and other&#xD;
      transformed T-cell lymphomas with the primary objective of studying the biological effects of&#xD;
      the multikinase inhibitor, sorafenib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives:&#xD;
&#xD;
      â€¢ To study the biological effects of sorafenib 400mg BID on the mitogen-activated protein&#xD;
      kinase (MAPK) pathway, specifically the inhibition of extracellular signal-regulated kinases&#xD;
      (ERK) phosphorylation, and to correlate with clinical activity in patients with T-cell&#xD;
      lymphoma.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To observe the clinical activity of sorafenib 400mg BID by determining response rate,&#xD;
           and progression free survival in patients with T-cell lymphoma. Duration of response and&#xD;
           duration of stable disease will also be measured.&#xD;
&#xD;
        -  To determine the tolerability of sorafenib in patients with T-cell lymphoma.&#xD;
&#xD;
      Exploratory objectives:&#xD;
&#xD;
        -  To observe the effects of sorafenib on T-cell subsets (CD4/CD8 ratio, and Tregs), and&#xD;
           the effects of sorafenib on the monocytoid population.&#xD;
&#xD;
        -  To observe the effects of sorafenib on the serum cytokine profile.&#xD;
&#xD;
        -  To observe the effects of sorafenib on the T-cell receptor pathway, i.e. Lck, ZAP-70,&#xD;
           and Syk.&#xD;
&#xD;
        -  To observe changes in lymph node or skin morphology including tumor cell infiltrate,&#xD;
           vasculature, and the tumor microenvironment in patients treated with sorafenib by&#xD;
           performing serial biopsies of lymph nodes or skin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>29 days</time_frame>
    <description>Overall response rate to sorafenib. Complete response by recist criteria was complete disappearance of all tumor lesions. partial response was 30% reduction in all sites of disease.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib, 400 mg PO twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.</description>
    <arm_group_label>Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed T-cell lymphoma including PTCL, AITL, CTCL, ALCL (Alk+, and&#xD;
             Alk-), and other transformed T-cell lymphomas&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Measureable disease, as defined by the Cheson criteria&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function&#xD;
&#xD;
          -  Patients with hemoglobin &lt; 8.5g/dL, or ANC 500-1000/mm3, or platelets&#xD;
             50,000-75,000/mm3 (Grade 3), whose cytopenias are due to bone marrow involvement by&#xD;
             T-cell lymphoma will also be eligible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with sorafenib, or other agents with similar activity, i.e.&#xD;
             bevacizumab, imatinib, sunitinib.&#xD;
&#xD;
          -  Prior treatment with allogeneic stem cell transplant&#xD;
&#xD;
          -  Cardiac disease: Congestive heart failure &gt; class II NYHA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francine Foss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2012</study_first_posted>
  <results_first_submitted>June 15, 2016</results_first_submitted>
  <results_first_submitted_qc>August 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2020</results_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed or refractory T cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib</title>
          <description>Sorafenib, 400 mg PO twice daily&#xD;
Sorafenib: Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib</title>
          <description>Sorafenib, 400 mg PO twice daily&#xD;
Sorafenib: Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age in years</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="38" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Overall response rate to sorafenib. Complete response by recist criteria was complete disappearance of all tumor lesions. partial response was 30% reduction in all sites of disease.</description>
        <time_frame>29 days</time_frame>
        <population>all patients enrolled were assessed for response</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib</title>
            <description>sorafenib</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Overall response rate to sorafenib. Complete response by recist criteria was complete disappearance of all tumor lesions. partial response was 30% reduction in all sites of disease.</description>
          <population>all patients enrolled were assessed for response</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib</title>
          <description>sorafenib</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Francine Foss MD</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>2037375312</phone>
      <email>francine.foss@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

